EAM
BNTC icon

Empery Asset Management’s Benitec Biopharma BNTC Stock Holding History

Empery Asset Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Sell
30,440
-25,000
-45% -$289K 0.39% 17
2025
Q4 		$747K Buy
+55,440
New +$767K 0.66% 17
2022
Q3 		$296K Buy
+46,873
New +$596K 1.76% 16

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Empery Asset Management's BNTC Position: Q1 2026 in Review

Empery Asset Management reduced its Benitec Biopharma (BNTC) stake by 45% in Q1 2026, selling an estimated $289K and leaving 30,440 shares worth $324K. The position accounts for 0.39% of the portfolio, ranked #17.

Empery Asset Management first reported a position in BNTC in Q3 2022 and has held it in 3 quarters since. The position peaked at $747K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Empery Asset Management held 30,440 shares of Benitec Biopharma worth $324K as of Q1 2026.
  • Empery Asset Management sold 25,000 Benitec Biopharma shares in Q1 2026, an estimated $289K.
  • Benitec Biopharma made up 0.39% of Empery Asset Management's portfolio in Q1 2026, its #17 holding.
  • Empery Asset Management first reported a position in Benitec Biopharma in Q3 2022 and has held it in 3 quarters since.
  • Empery Asset Management's Benitec Biopharma position peaked at $747K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Empery Asset Management's 13F filing for Q1 2026, filed 8 May 2026.